Wall Street brokerages forecast that Can-Fite Biopharma Ltd (NASDAQ:CANF) will announce earnings per share (EPS) of ($0.13) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Can-Fite Biopharma’s earnings. Can-Fite Biopharma posted earnings of ($0.10) per share during the same quarter last year, which would indicate a negative year over year growth rate of 30%. The business is expected to report its next earnings results on Friday, June 7th.
According to Zacks, analysts expect that Can-Fite Biopharma will report full-year earnings of ($0.55) per share for the current financial year. For the next financial year, analysts anticipate that the firm will report earnings of $0.12 per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Can-Fite Biopharma.
Separately, HC Wainwright reissued a “buy” rating on shares of Can-Fite Biopharma in a report on Tuesday, March 26th.
About Can-Fite Biopharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.
Further Reading: Net Asset Value
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Can-Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.